Exelixis, Inc. (LON: 0IJO)
London
· Delayed Price · Currency is GBP · Price in USD
33.15
0.00 (0.00%)
At close: Jan 31, 2025
Exelixis Employees
Exelixis had 1,310 employees as of December 31, 2023. The number of employees increased by 87 or 7.11% compared to the previous year.
Employees
1,310
Change (1Y)
87
Growth (1Y)
7.11%
Revenue / Employee
1.19M GBP
Profits / Employee
265.93K GBP
Market Cap
7.62B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
Hikma Pharmaceuticals | 9,100 |
ConvaTec Group | 10,136 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Exelixis News
- 4 days ago - Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 - Business Wire
- 6 days ago - This Twilio Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
- 8 days ago - Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025 - Business Wire
- 8 days ago - Exelixis Inc (EXEL) Announces Promising Results from CABINET Study for GI Neuroendocrine Tumors - GuruFocus
- 8 days ago - Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025 - Business Wire
- 8 days ago - Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33? - GuruFocus
- 9 days ago - Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns - GuruFocus
- 9 days ago - Exelixis downgraded by Oppenheimer to perform - Seeking Alpha